New Treatment for Obesity More Effective than "Diabetes Injections"

A new treatment under study by the Danish pharmaceutical company "Novo Nordisk" shows double effectiveness against obesity compared to its successful treatments "Ozempic" and "Wegovy," according to preliminary laboratory results that have quickly reassured the financial markets. With "amicrotin," weight loss reached 13% within three months, based on the results of the first phase of a clinical trial conducted on 16 participants and announced by the company. Previous trials indicated a weight loss of approximately 6% over the same period with the "Ozempic" and "Wegovy" treatments produced by "Novo Nordisk." However, experts emphasized the need for further research to evaluate the long-term effectiveness and safety of "amicrotin." Nevertheless, the announcement sparked interest in the stock market, with shares of "Novo Nordisk," listed on the Copenhagen Stock Exchange, rising by more than 8% on Thursday. The popularity of the new generation of diabetes treatments, also used to combat obesity, has made "Novo Nordisk" the leading company in Europe in terms of market capitalization and a key driver of the Danish economy, leading to shortages in stock. In contrast to other medications based on the active ingredient semaglutide, including "Ozempic," "Wegovy," or "Mounjaro" (produced by "Eli Lilly"), "amicrotin" is administered in tablet form rather than as a weekly injection.